---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-067012"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:38:05.607069+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M

## Summary
- Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).
- Revenue Q4 $17.8M (up 5% YoY); full year $88.0M (up 376% YoY) from Bayer tech transfer $52.4M and Sanofi milestones $15.0M.
- Cash $1.22B at Dec 31 2025; Q4 cash burn ~$134M excluding $100M loan draw from Royalty Pharma.
- MYQORZO (aficamten) approved for oHCM in US (Dec 2025), China, EU; US launch underway Jan 2026; ACACIA-HCM topline expected Q2 2026.
- FY 2026 GAAP combined R&D+SG&A guidance $830-870M; non-cash stock comp $130-120M.

## SEC filing metadata
- accession: 0001193125-26-067012
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/0001193125-26-067012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-067012
- JSON: https://secwatch.observer/filing/0001193125-26-067012.json
- Plain text: https://secwatch.observer/filing/0001193125-26-067012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.